Shandong Sito Bio-technology Co (SZSE:300583) ROCE % : -4.24% (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Shandong Sito Bio-technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shandong Sito Bio-technology Co's annualized ROCE % for the quarter that ended in Mar. 2025 was -4.24%.

Shandong Sito Bio-technology Co ROCE % Historical Data

The historical data trend for Shandong Sito Bio-technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Sito Bio-technology Co ROCE % Chart

Shandong Sito Bio-technology Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-8.03

4.42

4.43

4.38

-3.38

Shandong Sito Bio-technology Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															3.30	3.16	1.51	-22.46	-4.24

Shandong Sito Bio-technology Co ROCE % Calculation

Shandong Sito Bio-technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-71.896	/	( ( (3240.242 - 986.759)	+	(3025.807 - 1023.672) )	/ 2 )
	=	-71.896	/	( (2253.483	+	2002.135)	/ 2 )
	=	-71.896	/	2127.809
	=	-3.38 %

Shandong Sito Bio-technology Co's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-83.932	/	( ( (3025.807 - 1023.672)	+	(2936.417 - 976.342) )	/ 2 )
	=	-83.932	/	( ( 2002.135	+	1960.075 )	/ 2 )
	=	-83.932	/	1981.105
	=	-4.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Shandong Sito Bio-technology Co (SZSE:300583) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shandong Sito Bio-technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Shandong Sito Bio-technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Sito Bio-technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Sito Bio-technology Co Ltd (SZSE:300583) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

South Section of East Outer Ring Road, Dingtao District, Shandong Province, Heze, CHN, 274100

Website

http://www.sitobiotech.com

Shandong Sito Bio-technology Co Ltd is a biotechnology company. It uses genetic engineering technology and microbial transformation technology to develop and produce steroid drug raw materials, specialty respiratory raw materials and finished preparations, and other drug intermediaries. The company operates in the following business segments; intermediates, high-end specialty respiratory APIs, and preparations. Its product offerings include androstenedione (AD), 9-hydroxy androstenedione (90H-AD), 17a-hydroxyprogesterone derivatives (A ring), and bi-decanoic acid (BA), and others. In addition, the company holds patents for various APIs and other intermediaries.

Executives

Mi Qi	Directors, executives
Wang Min	Director
Kong Qing Zhi	Executives
He Jian Yong	Directors, executives
Ceng Qing Li	Securities Affairs Representative

Shandong Sito Bio-technology Co Headlines

No Headlines